J. Romaguera

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infusional Vinorelbine in Relapsed or Refractory Lymphomas

P. Mclaughlin, A. Psyrri, L. Medeiros, 2000, Leukemia & lymphoma.

Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen

Terry L. Smith, Maria A. Rodriguez, P. Mclaughlin, 2005, Cancer.

Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study.

D. Moore, F. Cabanillas, A. Sarris, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

J. Shah, W. Murphy, P. Mclaughlin, 2013, Clinical lymphoma, myeloma & leukemia.

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

Michael L. Wang, L. Kwak, L. Fayad, 2012, Blood.

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2013, Clinical lymphoma, myeloma & leukemia.

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

B. Esmaeli, P. Mclaughlin, F. Cabanillas, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.

Michael L. Wang, L. Kwak, Liang Zhang, 2010, Blood.

Clinical value of magnetic resonance imaging and other baseline testing for conjunctival mucosa-associated lymphoid tissue lymphoma

B. Esmaeli, P. Mclaughlin, Margaret L. Pfeiffer, 2014, Leukemia & lymphoma.

Spontaneous regression of mantle cell lymphoma: a report of four cases

Michael L. Wang, K. Nomie, A. Desai, 2018, Cancer communications.

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.

Christine F. Wogan, Y. Oki, F. Turturro, 2015, International journal of radiation oncology, biology, physics.

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Maria A. Rodriguez, Y. Oki, Ying Yuan, 2012, Blood.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2008, Cancer.

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

L. Gordon, A. Younes, L. Kwak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

Michael L. Wang, Y. Oki, K. Young, 2016, The Lancet. Oncology.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Michael L. Wang, Y. Oki, A. Younes, 2014, British journal of haematology.

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, British journal of haematology.

Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients.

Michael L. Wang, P. Allen, L. Medeiros, 2014, Clinical lymphoma, myeloma & leukemia.

Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma

Michael L. Wang, Shouhao Zhou, Q. Cai, 2014, Oncotarget.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2013, British journal of haematology.

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T‐cell lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2013, British journal of haematology.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

J. Shah, J. Wood, P. Mclaughlin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Usefulness of flow cytometric immunophenotyping for bone marrow staging in patients with mantle cell lymphoma after therapy.

L. Medeiros, Wei Liu, J. Jorgensen, 2012, American journal of clinical pathology.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT‐guided percutaneous lung biopsies in patients with haematologic malignancies and undiagnosed pulmonary lesions

K. Ahrar, S. Krishnamurthy, Sanjay Gupta, 2009, Hematological oncology.

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.

Michael L. Wang, L. Kwak, L. Fayad, 2012, Experimental hematology.

A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma

Michael L. Wang, H. Lee, J. Romaguera, 2020, British journal of haematology.

Current regimens and novel agents for mantle cell lymphoma

Michael L. Wang, J. Romaguera, Yiming Chen, 2014, British journal of haematology.

Trimetrexate in relapsed T-cell lymphoma with skin involvement.

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary hepatic lymphoma

L. North, F. Cabanillas, B. Osborne, 2001, Cancer.

Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases

J. Manning, F. Cabanillas, F. Ravandi, 2000, Leukemia & lymphoma.

The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.

J. Manning, J. Cox, F. Cabanillas, 2000, International journal of radiation oncology, biology, physics.

Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1998, Leukemia & lymphoma.

Paclitaxel plus high‐dose cyclosphosphamide with G‐CSF support in patients with relapsed and refractory aggressive non‐Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 1998, British journal of haematology.

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.

B. Andersson, U. Popat, M. de Lima, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2010, British journal of haematology.

Phase 2 trial of rituximab plus hyper‐CVAD alternating with rituximab plus methotrexate‐cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Michael L. Wang, Maria A. Rodriguez, H. Kantarjian, 2008, Cancer.

Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Investigational New Drugs.

Can we Identifv Patients with Low Grade Lymphom; for Frontline ABMT?

J. Romaguera, 1993 .

Can we identify patients with low grade lymphoma for frontline ABMT?

J. Romaguera, 1993, Leukemia & lymphoma.

Gallium Scan after the Second and Fourth Chemotherapy Cycle is Predictive in Aggressive Non-Hodgkin ’ s Lymphomas

Maria A. Rodriguez, D. Podoloff, P. Mclaughlin, 2012 .

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.

P. Mclaughlin, F. Cabanillas, F. Hagemeister, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2018, Head & neck.

Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma

Michael L. Wang, Y. Oki, B. Esmaeli, 2017, Head and Neck.

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

Christine F. Wogan, Y. Oki, A. Milbourne, 2016, JAMA oncology.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

D. Chihara, C. Cheah, R. Champlin, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2018, British journal of haematology.

Frontline Treatment for Older Patients with Mantle Cell Lymphoma.

Michael L. Wang, A. Desai, Haige Ye, 2018, The oncologist.

Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy in mantle cell lymphoma: Anti‐CD20‐based therapy and beyond

Michael L. Wang, L. Kwak, Liang Zhang, 2008, American journal of hematology.

De novo CD5+ Burkitt lymphoma/leukemia.

H. Kantarjian, T. Manshouri, M. Albitar, 1999, American journal of clinical pathology.

Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production

Michael L. Wang, L. Kwak, L. Fayad, 2012, British journal of haematology.

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

T. Pan, Y. Oki, A. Younes, 2014, British journal of haematology.

Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

P. Mclaughlin, A. Younes, L. Kwak, 2019, British journal of haematology.

High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2017, British journal of haematology.

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low‐grade B‐cell lymphomas

P. Mclaughlin, A. Younes, L. Kwak, 2015, British journal of haematology.

High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria.

P. Mclaughlin, R. Orlowski, L. Kwak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-time 5'-->3' exonuclease-based PCR assay for detection of the t(11;14)(q13;q32).

L. Medeiros, A. Sarris, A. Paladugu, 1999, American journal of clinical pathology.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

P. Mclaughlin, J. Manning, L. Medeiros, 2003, Cancer.

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Michael L. Wang, Y. Oki, H. Kantarjian, 2018, Cancer.

90Y‐ibritumomab tiuxetan radiotherapy as first‐line therapy for early stage low‐grade B‐cell lymphomas, including bulky disease

P. Mclaughlin, L. Kwak, R. Mathur, 2014, British journal of haematology.

Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

Y. Oki, A. Younes, L. Fayad, 2012, Blood.

Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.

Michael L. Wang, Maria A. Rodriguez, Y. Oki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.

P. Mclaughlin, F. Cabanillas, M. Overman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

Michael L. Wang, A. Younes, L. Fayad, 2006, European journal of cancer.

A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.

Maria A. Rodriguez, S. Tucker, P. Mclaughlin, 2003, International journal of radiation oncology, biology, physics.

Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma

Maria A. Rodriguez, L. Fuller, P. Mclaughlin, 2003 .

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Y. Oki, E. Shpall, A. Younes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

Maria A. Rodriguez, P. Mclaughlin, A. Younes, 2006, Leukemia & lymphoma.

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

P. Mclaughlin, F. Cabanillas, A. Younes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

L. Kwak, L. Fayad, S. Neelapu, 2011, Blood.

TCL 1 : a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

L. Kwak, L. Fayad, S. Neelapu, 2012 .

The Use of Salivary Protein Secretions as an In Vivo Model to Study Mantel Cell Lymphoma Progression and Treatment

C. Streckfus, J. Romaguera, Cynthia Guajardo-Streckfus, 2013, Cancer investigation.

Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment

S. Neelapu, N. McCarty, J. Romaguera, 2016, Oncotarget.

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

Deborah A. Thomas, L. Fayad, J. Romaguera, 2007, Clinical lymphoma & myeloma.

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Y. Oki, Y. Nieto, D. Chihara, 2018, Haematologica.

(FND) plus rituximab and interferon alpha indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone Myelodysplasia and acute myeloid leukemia following therapy for

E. Estey, P. Mclaughlin, A. Glassman, 2013 .

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

E. Estey, P. Mclaughlin, A. Glassman, 2004, Blood.

Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

L. Fayad, G. Cohen, B. Pro, 2004 .

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 1999 .

Endocrine characterization of primary mediastinal lymphoma.

F. Cabanillas, J. Romaguera, T. Brooks, 1996, Leukemia & lymphoma.

Primary mediastinal large cell lymphoma

José Raúl Rodríguez Rodríguez, J. Romaguera, W. Pugh, 1994, Hematological oncology.

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

Maria A. Rodriguez, P. Mclaughlin, F. Cabanillas, 2012, Leukemia & lymphoma.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

P. Mclaughlin, R. Orlowski, C. Bueso-Ramos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Michael L. Wang, R. Couch, P. Mclaughlin, 2006, The Journal of infectious diseases.

Indolent peripheral T-cell lymphoma involving the gastrointestinal tract.

Y. Oki, J. Manning, L. Medeiros, 2014, Human pathology.

Anaplastic Ki-1 + large-cell lymphoma.

F. Cabanillas, J. Romaguera, W. Pugh, 1993, Cancer investigation.

CD20+ nodal marginal zone B-cell lymphoma with CD20–recurrence as an intracranial dural-based mass

L. Medeiros, J. Romaguera, A. Wedgwood, 2006, Leukemia & lymphoma.

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors

Michael L. Wang, Y. Oki, P. Jain, 2018, British journal of haematology.

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Maria A. Rodriguez, F. Cabanillas, N. Dang, 2004 .

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study.

F. Cabanillas, N. Dang, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Michael L. Wang, K. Nomie, R. Champlin, 2018, Journal of Experimental & Clinical Cancer Research.

Proliferation predicts failure‐free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high‐dose methotrexate and cytarabine

G. Rassidakis, L. Medeiros, J. Romaguera, 2009, Cancer.

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, American journal of hematology.

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2019, Blood.

Mantle cell lymphoma: Frontline and salvage therapy

J. Romaguera, 2008, Current hematologic malignancy reports.

A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, P. Mclaughlin, 2004 .

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

L. Gordon, A. Younes, L. Kwak, 2009 .

Real-Time RT-PCR Assay for Quantifying Cyclin D1 mRNA in B-Cell Non-Hodgkin's Lymphomas

L. Medeiros, R. Luthra, V. Thomazy, 2002, Modern Pathology.

Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.

P. Mclaughlin, F. Cabanillas, A. Sarris, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis.

L. Fuller, P. Mclaughlin, F. Cabanillas, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

R. Davis, V. Baladandayuthapani, Wencai Ma, 2014, The Lancet. Oncology.

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

P. Mclaughlin, L. Medeiros, A. Younes, 2005 .

Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.

J. Murray, B. Esmaeli, P. Mclaughlin, 2002, Archives of ophthalmology.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

B. Coiffier, C. Gisselbrecht, M. Crump, 2015, Experimental Hematology & Oncology.

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

L. Fayad, J. Shah, J. Romaguera, 2008, Blood.

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.

L. Fuller, F. Cabanillas, F. Cabanillas, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.

L. North, A. Younes, F. Hagemeister, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

M. Suarez‐Almazor, A. Lok, S. Cantor, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy

B. Coiffier, A. Strahs, G. Verhoef, 2008 .

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

D. Berry, S. Faria, L. Medeiros, 2011 .

High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma.

L. Fuller, F. Cabanillas, J. Cox, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2010, British journal of haematology.

Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation.

W. Symmans, F. Cabanillas, N. Ordóñez, 1995, Acta cytologica.

Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

R. Kurzrock, P. Mclaughlin, L. North, 1997, British journal of haematology.

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma

J. Singer, L. Fayad, G. Cohen, 2011, Cancer.

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

P. Mclaughlin, F. Cabanillas, A. Younes, 2006, Leukemia & lymphoma.

Follicular large cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Fayad, 1999 .

Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Michael L. Wang, P. Jain, R. Kanagal-Shamanna, 2018, British journal of haematology.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael L. Wang, R. Advani, K. Blum, 2012 .

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Michael L. Wang, R. Advani, W. Jędrzejczak, 2013, The New England journal of medicine.

Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas

F. Cabanillas, J. Cox, R. Wilder, 2002, Leukemia & lymphoma.

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

I. Flinn, P. Mclaughlin, F. Cabanillas, 2004, Clinical Cancer Research.

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy

Michael L. Wang, Liang Zhang, M. Desai, 2013, Journal of Hematology & Oncology.

Interferon-induced retinopathy in asymptomatic cancer patients.

B. Esmaeli, J. Romaguera, N. Papadopoulos, 2001, Ophthalmology.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

Michael L. Wang, J. Shah, M. Wang, 2013, Leukemia.

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

B. Coiffier, A. Berkenblit, C. Gisselbrecht, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

K. Kliche, M. Andreeff, S. Tucker, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas.

F. Cabanillas, P. Allen, F. Hagemeister, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.

W. Velasquez, P. Mclaughlin, L. North, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981.

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 1999, Blood.

Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.

F. Cabanillas, L. Medeiros, A. Sarris, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy.

P. Mclaughlin, F. Cabanillas, J. Cox, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy

P. Mclaughlin, J. Cox, F. Cabanillas, 2001 .

Lymphomas The Clinical Significance of Molecular Response in Indolent Follicular

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2013 .

Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1999, Blood.

The clinical significance of molecular response in indolent follicular lymphomas.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 1998, Blood.

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Y. Oki, F. Turturro, Y. Nieto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

J. Cox, F. Cabanillas, B. Andersson, 2004, Bone Marrow Transplantation.

CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.

G. Bonadonna, P. Mclaughlin, F. Cabanillas, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.

A. Bleyer, F. Cabanillas, L. Medeiros, 2002, Oncology.

Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma)

Michael L. Wang, Shaoying Li, K. Nomie, 2018, American journal of clinical oncology.

Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.

A. López-Guillermo, P. Mclaughlin, F. Cabanillas, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical relevance of t(14;18)/BCL-2 rearrangement and DEL 6q in diffuse large cell lymphoma and immunoblastic lymphoma.

F. Cabanillas, A. Goodacre, J. Romaguera, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.

Michael L. Wang, L. Kwak, N. Caraway, 2010, Stem cell research.

Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.

P. Mclaughlin, F. Cabanillas, M. Keating, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.

Terry L. Smith, L. Fuller, P. Mclaughlin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

P. Mclaughlin, J. Cox, F. Cabanillas, 1998, Blood.

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Michael L. Wang, R. Advani, W. Jędrzejczak, 2015, Blood.

Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways.

Michael L. Wang, Liang Zhang, Sungyoul Hong, 2006, Blood.

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

S. Tucker, W. Velasquez, P. Mclaughlin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R‐CHOP

Michael L. Wang, Y. Oki, M. Overman, 2018, Clinical lymphoma, myeloma & leukemia.

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.

R. Davis, Y. Oki, F. Turturro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

lymphoma alternating triple therapy (ATT) regimen in patients with stage IV indolent Fludarabine, mitoxantrone, dexamethasone (FND) compared with an

P. Mclaughlin, F. Cabanillas, A. Tsimberidou, 2013 .

Rosai-Dorfman disease misdiagnosed as active tuberculosis

Daniel M. Jones, A. Gillenwater, A. Safdar, 2006, Leukemia & lymphoma.

Long-term prognostic importance of primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large-cell lymphoma.

J. Manning, N. Ordóñez, A. Goodacre, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial

Jeffrey E. Lee, R. Winn, Yu Shen, 1999, Annals of Internal Medicine.

Detection of Chromosome 11 q 13 Breakpoints by Interphase Fluorescence In Situ Hybridization

F. Jiang, F. Cabanillas, L. Medeiros, 2002 .

Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma.

F. Jiang, L. Medeiros, N. Caraway, 2000, American journal of clinical pathology.

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.

Michael L. Wang, V. Baladandayuthapani, Dajun Yang, 2011, Blood.

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

P. Mclaughlin, F. Cabanillas, K. Young, 2012, The Lancet. Oncology.

Evaluation of peripheral blood involvement of mantle cell lymphoma by fluorescence in situ hybridization in comparison with immunophenotypic and morphologic findings

F. Jiang, N. Caraway, J. Gu, 2004, Modern Pathology.

A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'.

P. Mclaughlin, F. Cabanillas, F. Hagemeister, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Michael L. Wang, R. Davis, J. Shah, 2014, The Lancet. Oncology.

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

G. Ayers, S. Verstovsek, P. Mclaughlin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, Blood advances.

Use of bortezomib in B-cell non-Hodgkin’s lymphoma

Michael L. Wang, Liang Zhang, J. Romaguera, 2006, Expert review of anticancer therapy.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Michael L. Wang, Y. Oki, F. Turturro, 2014, British journal of haematology.

Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2013, PloS one.

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2‐microglobulin level in patients with diffuse large b‐cell lymphoma: a new prognostic model

Michael L. Wang, Y. Oki, P. Mclaughlin, 2016, British journal of haematology.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Michael L. Wang, L. Fayad, J. Westin, 2019, Haematologica.

The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia

F. Turturro, H. Torres, J. Romaguera, 2014, Leukemia & lymphoma.

Multiple Myeloma, Painful Neuropathy, Acupuncture?

Michael L. Wang, A. Forman, Q. Yi, 2009, American journal of clinical oncology.

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study

Michael L. Wang, R. Orlowski, Liang Zhang, 2014, Journal of Hematology & Oncology.

A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

H. Kantarjian, F. Cabanillas, A. Younes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2000, Leukemia & lymphoma.

Smoldering mantle cell lymphoma

Michael L. Wang, K. Nomie, A. Desai, 2017, Journal of experimental & clinical cancer research : CR.

Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?

F. Cabanillas, L. Medeiros, A. Sarris, 2001, Clinical lymphoma.

The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy.

D. Podoloff, F. Cabanillas, F. Hagemeister, 1994, Annals of Oncology.

Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?

H. Kantarjian, J. Cortes, J. Manning, 2011, Current hematologic malignancy reports.

Mantle-cell lymphoma.

F. Cabanillas, J. Romaguera, I. Barista, 2001, The Lancet. Oncology.

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

H. Kantarjian, F. Cabanillas, M. Albitar, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

W. Chan, K. Fu, J. Vose, 2015, British journal of haematology.

Current trials for frontline therapy of mantle cell lymphoma

J. Romaguera, R. Steiner, Michael Wang, 2018, Journal of Hematology & Oncology.

Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.

S. Tucker, W. Velasquez, P. Mclaughlin, 1995, Leukemia & lymphoma.

Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature

L. Fayad, M. Thompson, F. Hagemeister, 2007, American journal of hematology.

Integrated stress response and immune cell infiltration in an ibrutinib‐refractory mantle cell lymphoma patient following ONC201 treatment

Michael L. Wang, Evita T. Sadimin, J. Schenkel, 2019, British journal of haematology.

A Multidisciplinary Approach to Cancer

J. Westin, J. Romaguera, 2012 .

Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study

P. Mclaughlin, A. Younes, B. Dabaja, 2012, Leukemia & lymphoma.

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, A. Younes, 2005, Bone Marrow Transplantation.

Activity of interferon‐α and isotretinoin in patients with advanced, refractory lymphoid malignancies

R. Kurzrock, A. Tsimberidou, F. Giles, 2004, Cancer.

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.

Michael L. Wang, Y. Oki, K. Nomie, 2017, The oncologist.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience

M. Munsell, N. Ueno, B. Andersson, 2008, Haematologica.

The survival outcome of patients with relapsed/refractory peripheral T‐cell lymphoma‐not otherwise specified and angioimmunoblastic T‐cell lymphoma

Michael L. Wang, Y. Oki, F. Turturro, 2017, British journal of haematology.

Impact of high-dose chemotherapy on peripheral T-cell lymphomas.

M. Munsell, F. Cabanillas, B. Andersson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2017, Blood.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS ASHAP: A Regimen for Cytoreduction of Refractory or Recurrent Hodgkin's Disease

P. Mclaughlin, F. Cabanillas, B. Andersson, 2016 .

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.

P. Mclaughlin, F. Cabanillas, B. Andersson, 1999, Blood.

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

P. Mclaughlin, F. Cabanillas, A. Younes, 1994, Investigational New Drugs.

Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma

Michael L. Wang, Y. Oki, F. Turturro, 2016, Cancer.

Impact o f H igh-Dose C hemotherapy o n P eripheral T -Cell Lymphomas

M. Munsell, F. Cabanillas, B. Andersson, 2001 .

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

P. Mclaughlin, F. Cabanillas, N. Dang, 2005 .

Paclitaxel (Taxol) for the treatment of lymphoma.

L. North, F. Cabanillas, A. Younes, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Double Hit Lymphoma: M.D. Anderson Experience

Michael L. Wang, Y. Oki, L. Kwak, 2013 .

Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma.

L. Fayad, R. Nunez, F. Hagemeister, 2006 .

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2003, Cancer.

Primary Effusion Lymphoma in an Hiv-Negative Patient with No Serologic Evidence of Kaposi's Sarcoma Virus

F. Cabanillas, J. Said, R. Katz, 2001, Leukemia & lymphoma.

Lymphoma of the colon

F. Hagemeister, J. Romaguera, 2005, Current opinion in gastroenterology.

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

Michael L. Wang, Y. Oki, F. Turturro, 2018, PloS one.

Novel chemotherapy‐free combination regimen for ibrutinib‐resistant mantle cell lymphoma

Michael L. Wang, K. Nomie, H. Lee, 2018, British journal of haematology.

CD5-negative Mantle Cell Lymphoma

Michael L. Wang, Shaoying Li, C. Yin, 2019, The American journal of surgical pathology.

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.

Christine F. Wogan, Y. Oki, E. Rohren, 2016, Clinical lymphoma, myeloma & leukemia.

Surgical debulking is associated with improved survival in stage I–II diffuse large cell lymphoma

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1990, Cancer.

CHOP-Bleo plus interferon for stage IV low-grade lymphoma.

W. Velasquez, P. Mclaughlin, F. Cabanillas, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2014, British journal of haematology.

Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients.

F. Cabanillas, A. Sarris, F. Hagemeister, 1998, Leukemia & lymphoma.

Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase.

F. Cabanillas, F. Cabanillas, R. Luthra, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).

P. Mclaughlin, D. Schenkein, L. Fayad, 2004, Journal of Clinical Oncology.

A Severe Combined Immunodeficient–hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma

Michael L. Wang, L. Kwak, Liang Zhang, 2008, Clinical Cancer Research.

The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine‐needle aspiration specimens

N. Caraway, J. Gu, R. Katz, 2005, Cancer.

Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper‐CVAD and rituximab, alternating with rituximab, high‐dose methotrexate, and cytarabine

G. Rassidakis, L. Medeiros, E. Drakos, 2009, Cancer.

A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma.

F. Cabanillas, N. Dang, E. Grimm, 2004, Journal of Clinical Oncology.

ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study.

Michael L. Wang, A. Younes, L. Fayad, 2005 .

Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?

F. Cabanillas, S. Strom, L. Medeiros, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.

P. Mclaughlin, L. North, F. Cabanillas, 1997, Leukemia & lymphoma.

16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma.

F. Cabanillas, J. García-Foncillas, J. Romaguera, 1995, Leukemia & lymphoma.

Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma

B. Leber, P. Mclaughlin, A. Younes, 2008, British journal of haematology.

Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial

Michael L. Wang, F. Turturro, Shaoying Li, 2016 .

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.

Christine F. Wogan, Y. Oki, F. Turturro, 2015, International journal of radiation oncology, biology, physics.

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Michael L. Wang, K. Nomie, R. Champlin, 2018, Journal of experimental & clinical cancer research : CR.

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

A Pilot Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Classical Hodgkin Lymphoma (HL): Delivering Cross Fire Radiation by Targeting Reactive B Cells in the Microenvironment.

P. Mclaughlin, A. Younes, F. Wong, 2005 .

Erratum to: Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma (Head Neck, (2017), 39, (1095–1100), 10.1002/hed.24717)

Michael L. Wang, Y. Oki, B. Esmaeli, 2018 .

A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy

L. Kwak, J. Zeldis, L. Fayad, 2007 .

Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2008 .

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.

S. Kondo, G. Georgakis, A. Younes, 2008, Experimental hematology.

SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy

Michael L. Wang, Y. Oki, E. Rohren, 2014 .

Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)

Y. Oki, M. Overman, F. Turturro, 2013 .

Mantle cell lymphoma with a rare involvement of the testicle

L. Medeiros, L. Fayad, J. Romaguera, 2007, Leukemia & lymphoma.

Thalidomide for patients with recurrent lymphoma

P. Mclaughlin, F. Cabanillas, M. Albitar, 2004, Cancer.

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

D. Chihara, C. Cheah, R. Champlin, 2015 .

Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial

Michael L. Wang, F. Turturro, L. Kwak, 2014 .

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

A. Younes, N. Dang, B. Pro, 2004 .

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

S. Faria, Y. Oki, L. Medeiros, 2012, Leukemia & lymphoma.

Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.

L. Fuller, P. Mclaughlin, F. Cabanillas, 1994, Seminars in hematology.

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Michael L. Wang, Y. Oki, P. Mclaughlin, 2012 .

Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011 .

Frontline antibiotic therapy for early‐stage Helicobacter pylori‐negative gastric MALT lymphoma

Michael L. Wang, Seung Tae Lee, C. Pinnix, 2019, American journal of hematology.

Follicular large cell lymphoma: Long-term follow-up of 62 patients

P. Mclaughlin, F. Cabanillas, L. Fayad, 2000 .

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Michael L. Wang, H. Lee, A. Zloza, 2017 .

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

P. Mclaughlin, A. Younes, L. Fayad, 2009 .

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Michael L. Wang, P. Mclaughlin, L. Kwak, 2008 .

Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL).

Michael L. Wang, Y. Oki, D. Podoloff, 2006 .

IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO

F. Turturro, S. Huang, Suping Zhou, 2017 .

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.

Christine F. Wogan, Y. Oki, F. Turturro, 2015, International journal of radiation oncology, biology, physics.

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

L. Kwak, L. Fayad, S. Neelapu, 2011, Blood.

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Michael L. Wang, Y. Oki, A. Younes, 2014, British journal of haematology.

Prospective phase II study of rituximab with alternating cycles of hyper‐CVAD and high‐dose methotrexate with cytarabine for young patients with high‐risk diffuse large B‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2013, British journal of haematology.

Smoldering mantle cell lymphoma

Michael L. Wang, K. Nomie, A. Desai, 2017, Journal of Experimental & Clinical Cancer Research.

International prognostic index‐based outcomes for diffuse large B‐cell lymphomas

S. Tucker, F. Cabanillas, L. Medeiros, 2002, Cancer.

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Michael L. Wang, H. Kantarjian, P. Mclaughlin, 2016, British journal of haematology.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael L. Wang, A. Younes, J. Zeldis, 2008 .

G. Rassidakis, L. Medeiros, J. Romaguera, 2009, Cancer.

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

P. Mclaughlin, A. Younes, L. Kwak, 2010 .

Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, L. Fayad, 2005 .

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .

Molecular Signatures of Tumor-Initiating Cells Unveil Wnt Pathway As a Therapeutic Target in Mantle Cell Lymphoma

Michael L. Wang, R. Mathur, S. Neelapu, 2014 .

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, Clinical lymphoma, myeloma & leukemia.

Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma

Y. Oki, Jiexin Zhang, Shouhao Zhou, 2013, Clinical Cancer Research.

Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy.

P. Mclaughlin, A. Younes, L. Fayad, 2007 .

NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.

W. Velasquez, F. Cabanillas, M. Meistrich, 1990, Seminars in oncology.

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non‐Hodgkin lymphoma

J. Singer, L. Fayad, G. Cohen, 2011, Cancer.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2009 .

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Michael L. Wang, Linghua Wang, K. Patel, 2019, Blood.

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

P. Mclaughlin, F. Cabanillas, M. Overman, 2007 .